1月21日 - ** 药物开发商 Zura Bio ZURA.O 的股票在早盘交易中上涨 9.18% 至 5.47 美元
** 公司任命Zura董事会董事库尔卡尼（Sandeep Kulkarni）接替利斯基（Robert Lisicki）担任首席执行官
** 库尔卡尼早先与他人共同创办了电气石生物公司，该公司后来被诺华NOVN.S收购。
** 即将离任的首席执行官利斯基已于 10 月份开始休病假，由金-戴维斯（Kim Davis）临时接任。
** 公司的主导药物替布珠单抗正处于治疗化脓性扁桃体炎和系统性硬化症的中期试验阶段，这两种疾病都是长期的自身免疫性疾病。
** 公司称关键试验结果有望在 18 个月内公布
** 2025 年股价上涨约 110%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.